Innovative therapies in cutaneous & indolent systemic mastocytosis
European initiative to improve therapeutic options for patients with indolent systemic and cutaneous mastocytosis
The European Academy for Allergy and Clinical Immunology (EAACI) installed a Task Force to improve the treatment of symptoms in indolent systemic and cutaneous mastocytosis.
Mastocytosis is characterized by an abnormal increase of mast cells in various tissues. Most patients with mastocytosis suffer from benign indolent systemic mastocytosis and/or cutaneous mastocytosis and may have symptoms that are caused by the release of inflammatory mediators from mast cells. As of today, therapeutic options to cure mastocytosis are not available. Therefore, the treatment of annoying symptoms is one of the most important tasks to maintain and improve the life quality of patients. However, sufficient relieve of symptoms is not available for many patients because standard treatment options often lack efficacy.
The European Academy for Allergy and Clinical Immunology has established a Task Force in which world leading experts come together and work out strategies to improve the current therapeutic situation in mastocytosis.